Professor at Harvard Medical School and Senior Research Associate at Partners in Health.
endTB Trial Paves Way for Shorter, Cheaper, and Safer Rifampin-Resistant TB Treatments
Carole Mitnick, ScD discusses the impact of the endTB trial's findings on future TB treatment options, including shorter treatment durations, lower costs, and expanded accessibility.
Read More
Five All-Oral Regimens Show Efficacy in the Phase 3 endTB Trial for Rifampin-Resistant TB
Carole Mitnick, ScD highlights the importance of trust in the success of the endTB trial and addresses the ongoing toxicity concerns with new shorter treatment regimens.